RecruitingNot applicableNCT05095571

A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Haukeland University Hospital
Principal Investigator
Ole-Bjørn Tysnes
Haukeland University Hospital
Intervention
EH301 (Nicotinamide Riboside/Pterostilbene)(dietary_supplement)
Enrollment
300 enrolled
Eligibility
35 years · All sexes
Timeline
20212026

Study locations (17)

Collaborators

Elysium Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05095571 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials